saplin

Invesco India Pharma and Healthcare Fund

Invesco India Pharma and Healthcare Fund (Direct, Growth): Not rated by saplin yet. Expense ratio 1.91%. NAV ₹10.53 on 11 Nov 2026.

Loading the full analysis…

Questions about Invesco India Pharma and Healthcare Fund

What is the expense ratio of Invesco India Pharma and Healthcare Fund?

The Direct plan's total expense ratio is 1.91% a year, against a median of 1.04% for sectoral/thematic funds. The Regular plan costs more because it pays a distributor's commission.

Who manages Invesco India Pharma and Healthcare Fund?

Aditya Khemani (since 7 Sept 2026).

What are the top holdings of Invesco India Pharma and Healthcare Fund?

Apollo Hospitals Enterprise 9.08%, Divi's Laboratories 8.74%, Max Healthcare Institute 8.59%, Sai Life Sciences 8.49%, Sun Pharmaceutical Industries 8.31% of the portfolio, as of 31 Oct 2026.

How big is Invesco India Pharma and Healthcare Fund?

About ₹111 cr (AMFI's average for the latest quarter).